Bio tech company updates — 10/9/2026
This health signal was created by a user. It may contain unverified medical claims. Always consult a qualified healthcare professional before making health decisions.
Korean biopharmaceutical exports reached a record $6.6 billion in the first three quarters of 2026, driven by strong European demand. Concurrently, Korean biotech firms are actively engaging in global partnership discussions at Bio Japan 2026 and pitching technologies to Japanese pharmaceutical giants like Otsuka Pharmaceutical to secure new contracts.
Key Findings
- Record Export Volume: South Korea's biopharmaceutical exports totaled $6.6 billion through the third quarter of 2026, marking a 15.8% year-over-year increase despite a decline in U.S. shipments.
- Active Global Collaboration: Major Korean contract development and manufacturing organizations (CDMOs), including Samsung Biologics and Lotte Biologics, are leveraging October's global events to secure new contracts.
- Bio Japan 2026 Engagement: Korean biotech companies are heavily participating in Bio Japan 2026 in Yokohama, with high interest in partnering and licensing deals.
- Targeted Technology Pitching: Six biotech firms from Korea's Daedeok research zone pitched their technologies directly to Otsuka Pharmaceutical in Tokyo on October 6.
Details
Record-Breaking Export Performance
South Korea has achieved a new milestone in its biopharmaceutical sector, with exports reaching $6.6 billion by the end of Q3 2026. This represents a 15.8% increase compared to the same period last year. The growth was primarily fueled by robust demand from European markets, which successfully offset a significant 23.7% drop in shipments to the United States.
Intensified Global Partnering Efforts
October has emerged as a critical month for Korean biotech firms seeking international collaboration. Companies such as Samsung Biologics and Lotte Biologics are actively pursuing new contracts and partnerships with local pharmaceutical and biotech entities abroad. Simultaneously, domestic biotech ventures are entering discussions for drug technology transfers and licensing agreements.
This push for collaboration is visibly evident at Bio Japan 2026, Asia's largest bio-pharmaceutical exhibition, which opened on October 7 at the Pacifico Convention Center in Yokohama. Industry professionals from various countries gathered early, indicating high demand for meetings and partnerships involving Korean biotech companies. The event serves as a major hub for K-Bio companies to showcase capabilities and negotiate deals.
Strategic Technology Pitches in Tokyo
Beyond large-scale exhibitions, targeted business development efforts are also underway. On October 6, six advanced biotech firms from Korea's Daedeok research zone conducted technology pitches at the Tokyo headquarters of Otsuka Pharmaceutical. This initiative highlights a strategy of direct engagement with major Japanese pharma companies to facilitate specific technology adoption and potential collaborations.
Sources
Phase 3 Data, Approvals, Licensing Deals: K-Bio Faces October Test - Seoul Economic Daily
October Packed with Global Events... Expanding Opportunities for Collaboration in K-Bio - The Asia B
mk.co.kr
en.sedaily.com
en.sedaily.com
en.sedaily.com
mk.co.kr
en.sedaily.com
en.edaily.co.kr
This content was collected, curated, and summarized entirely by AI — including how and what to gather. It may contain inaccuracies. Crew does not guarantee the accuracy of any information presented here. Always verify facts on your own before acting on them. Crew assumes no legal liability for any consequences arising from reliance on this content.
Powered by
